Many retail property-owning REITs reported third-quarter earnings in recent weeks, and the five specialists in net-leased retail properties had one thing in common: They were busy buying. Given the relative dearth of construction in the retail sector—Marcus & Millichap puts the construction pipeline at a mere 0.3% of existing inventory at midyear—it's not surprising that capitalization rates didn't necessarily increase during the latest quarter, despite the higher cost of capital. The 10-year Treasury yield averaged 4.76% in the third quarter,...

Read more

Osborne Clarke expands German patent litigation and life sciences regulatory team Osborne Clarke has added a patent litigation group to its Frankfurt office. It is led by new equity partner Nora Keßler and includes a counsel who can appear before the Unified Patent Court (UPC). In Munich, the firm has hired a life sciences regulatory counsel from White & Case. The new teams will cover national patent cases, arbitration and UPC proceedings, and healthcare and healthtech regulation. Why it matters: US...

Read more

Worley has signed a reimbursable engineering, procurement and construction contract with Venture Global for the CP2 Expansion at the CP2 LNG export terminal in Cameron Parish, Louisiana. The award builds on Worley’s existing EPC role on CP2 Phases 1 and 2. Its Houston, Baton Rouge and Reading teams will lead the work, and Venture Global is targeting a final investment decision in early 2027. More US LNG export capacity bears directly on Europe’s long-term gas supply and on transatlantic energy...

Read more

MILAN, Italy — While the global luxury sector faces a pronounced slowdown, Italian high-fashion house Brunello Cucinelli continues to demonstrate remarkable financial resilience. The brand announced it is raising its full-year 2026 sales growth expectations to 12%, bucking the downward economic trends currently plaguing massive multi-brand conglomerates like LVMH. Exceptional Third-Quarter Performance The upward revision follows a stellar third-quarter financial report. Driven by sustained demand across international markets, the luxury label achieved a 13.5% surge in third-quarter revenue, with sales reaching...

Read more

Belgian biopharmaceutical pioneer and EACCNY premium member Flen Health has achieved a critical regulatory milestone in its expansion into the United States healthcare market. The company announced a successful pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) for its highly anticipated topical drug candidate, VES gel. The advanced, enzyme-based formulation is designed specifically to treat chronic diabetic foot ulcers, a widespread and severe medical condition that currently lacks highly effective, rapid-healing therapeutic options. Following positive alignment...

Read more